Free Trial
→ The Iran War Just Broke the Gold Market (From Behind the Markets) (Ad)tc pixel
NASDAQ:ALEC

Alector Q1 2026 Earnings Report

Alector logo
$2.57 +0.06 (+2.39%)
Closing price 04:00 PM Eastern
Extended Trading
$2.57 +0.00 (+0.16%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Alector EPS Results

Actual EPS
N/A
Consensus EPS
-$0.29
Beat/Miss
N/A
One Year Ago EPS
N/A

Alector Revenue Results

Actual Revenue
N/A
Expected Revenue
$9.67 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alector Announcement Details

Quarter
Q1 2026
Date
5/14/2026
Time
Before Market Opens
Conference Call Date
Monday, May 11, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Alector Earnings Headlines

Retinal scan research offers hope for early Alzheimer’s detection
May 2 at 8:38 AM  |  msn.comhttps://www.msn.com/en-ca/news/other/retinal-scan-research-offers-hope-for-early-alzheimer-s-detection/gm-GM3700BC03
Alector, Inc. (NASDAQ:ALEC) Short Interest Down 18.0% in April
May 2 at 4:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30753872
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
May 5 at 1:00 AM  |  Brownstone Research (Ad)
Peninsula biotech Alector loses another Alzheimer's battle, shifts to earlier-stage programs
April 30, 2026  |  bizjournals.comhttps://www.bizjournals.com/sanfrancisco/news/2026/04/30/alector-alzheimers-trial-failure-trial-gsk.html
How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk
April 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/alector-alec-narrative-shifting-toward-120849477.html
Alector Stops Phase 2 Trial for Early Alzheimer's Treatment
April 30, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/alector-stops-phase-2-trial-for-early-alzheimer-s-treatment-cf96f89d
See More Alector Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email.

About Alector

Alector (NASDAQ:ALEC) is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies. Alector designs its molecules to engage key immune receptors in the brain, seeking to slow or halt disease progression rather than simply address symptoms. Research and development activities are supported by state-of-the-art laboratories in North America and collaborations with academic and industry partners in Europe.

Since completing its initial public offering in 2019, Alector has expanded its clinical footprint through strategic alliances and investigator-initiated trials. The company maintains global development programs aimed at bringing the first approved immuno-neurology therapies to patients worldwide.

Alector is led by co-founder and Chief Executive Officer Dr. Arnon Rosenthal, a neuroscientist with over two decades of experience in immunology and drug discovery. The management team brings extensive backgrounds in clinical development, regulatory affairs, and commercialization, supporting Alector’s mission to transform the treatment landscape for neurodegenerative diseases.

View Alector Profile
Earnings Tools